Compare Abeona Therapeutics Inc (ABEO) vs Duolingo Inc (DUOL) Price & Performance

ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.

Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.

Duolingo (DUOL) trades at $131.95, up 4.92% with strong technical momentum and bullish moving average signals. The company demonstrates exceptional fundamental strength with 2025 revenue reaching $1.04 billion and net income of $414 million, representing a 38.4% margin. Recent earnings beats and expanding profitability highlight operational excellence amid AI-driven product expansion into math and music learning.

Outlook remains positive with projected 2026 revenue growth to $1.1 billion, though the stock trades above analyst consensus target of $110.20. Key risks include competitive pressure in edtech and valuation concerns with P/E of 14.8 and P/S of 5.7. Institutional sentiment leans cautious with 59% hold ratings despite strong fundamentals.